Incruse Ellipta FDA Approval History
FDA Approved: Yes (First approved April 30, 2014)
Brand name: Incruse Ellipta
Generic name: umeclidinium
Dosage form: Inhalation Powder
Company: GlaxoSmithKline
Treatment for: COPD, Maintenance
Incruse Ellipta (umeclidinium) is an anticholinergic bronchodilator indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Development timeline for Incruse Ellipta
| Date | Article |
|---|---|
| May 1, 2014 | Approval FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
